menu

Global Phase I Network

Extensive Global Network of Sites to Meet Customers’ Needs

A focused network of leading partner sites to meet your global and local needs, at the center of which is our state of the art US Phase I Clinic. Our network provides a range of choices for healthy volunteers, patient and special populations to match protocol requirements.

Phase I expertise & experience on a global scale

Strategically located in Europe, the US, and Asia Pacific, our Phase I global network offers a comprehensive solution for your specific therapeutic area, geography, size and complexity.

Central & Western Europe

  • United Kingdom - FIH, PoC, PK/PD studies, access to biomarkers & imaging
  • Germany - FIH, PoC, PK/PD studies, access to biomarkers & imaging
  • Netherlands - FIH, PoC, PK/PD studies, access to biomarkers & imaging
  • Poland - Biosimilars & BE studies, large cohort capabilities/special population/naïve subject pop. access
  • Czech Republic - Biosimilars & BE studies, large cohort capabilities/special population/naïve subject pop. access

United States of America
Phase I USA

  • Kansas – Overland Park Flagship Phase I Unit with >80 beds, state of the art, custom designed Phase I clinic, >30 years’ experience, complex Phase I/IIa studies, >1000 FIH studies, and experience in CNS,  vaccines, endocrinology, hematology, respiratory, and oncology therapeutic areas
  • California - In-house influenza unit, Psychiatry, Enthnobridging, HCV/HBV, Renal, Diabetes, Asthma, Allergy, COPD, Rheumatoid Arthritis, Hypertension, CHF, CAD/PAD, Dermatology, Obesity
  • Florida - QTc, Cardiac Safety, FE, Biologics, PoC, MRI, fMRI, PET, SPECT, CT, DTI, image guided radiation therapy, and radiotracer
  • Minnesota - On-site DaVita dialysis unit, access to imaging and scanning (PET, MRI, DEXA), FIH/AD, CKD, ESRD, Hepatic, CV, Endocrine, Pulmonary, slow metabolizers
  • Colorado - FIH/Adaptive study design, CKD, ESRD, Hepatic, CV, Endocrine, Pulmonary, Gastrointestinal

Asia Pacific 

  • China - FIH, PoC, PK/PD, Biosimilar, BE
  • Korea - >2,000 patients, 180 studies
  • Singapore - >1,900 patients, 60 studies
  • Taiwan - FIH, PoC, PK/PD, BE
  • New Zealand - FIH, PoC, PK/PD, Biosimilar, ADME, BE
  • Philippines - >85 patients, 12 studies
  • Australia - FIH, PoC, PK/PD, Biosimilar, Clamp, BE

Are you a volunteer or patient looking to enroll in a Phase I study? Click here